Distinct patterns of pituitary dysfunction in combination immunotherapy with nivolumab and ipilimumab
Pituitary irAEs are more frequent and develop earlier in patients receiving Nivo/Ipi. CPHD and IAD, induced by this combination immunotherapy, exhibit distinct clinical courses. Recognizing these differences is crucial for the optimal management of pituitary irAEs during combination immunotherapy.
Authors
- Takuro Hakata
- Ichiro Yamauchi (ORCID: https://orcid.org/0000-0002-4236-502X)
- Taku Sugawa
- Sadahito Kimura
- Aya Sakurai
- Daisuke Kosugi
- Haruka Fujita (ORCID: https://orcid.org/0000-0002-2435-2014)
- Yohei Ueda
- Kentaro Okamoto
- Daisuke Yabe
- Daisuke Taura
Institutions
- Kyoto University (JP)
- Kyoto University Hospital (JP)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1093/ejendo/lvag031
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00